<!DOCTYPE html>
<html lang="en">
  <head>
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width, initial-scale=1.0">
	<title>Ranozex - USPs</title>
<style>
    body {
      font-family: Arial, sans-serif;
      background-color: #f4f9ff;
      margin: 0;
      padding: 20px;
      line-height: 1.6;
    }
    .product {
      background: #ffffff;
      padding: 20px;
      margin-bottom: 20px;
      border-radius: 10px;
      box-shadow: 0 2px 6px rgba(0, 0, 0, 0.1);
    }
    h2 {
      background-color: #0D9A9F;
      color: #fff;
      padding: 12px 20px;
      border-radius: 8px;
      box-shadow: 0 2px 4px rgba(0,0,0,0.1);
      font-size: 24px;
      margin-bottom: 20px;
    }
    h3 {
      color: #333;
      font-size: 18px;
      margin-top: 15px;
    }
    p {
      margin: 5px 0;
    }
    .bangla {
      font-family: 'Noto Sans Bengali', sans-serif;
    }
</style>
  </head>
  <body>
	<div class="product">
	  <h2>Ranozex</h2>
	  <p><strong>Highlighting Points / USPs</strong></p>

	  <ul>
		<li>Approved by <span class="highlight">US FDA</span> and <span class="highlight">EMEA</span>.</li>
		<li>It is a <span class="highlight">late sodium current inhibitor</span>, preventing sodium and calcium overload.</li>
		<li>Prevents ischemia at the cellular level.</li>
		<li>No change in HR or BP (No hemodynamic changes).</li>
		<li>According to MARISA Trial, Ranozex improves exercise performance.</li>
		<li>According to CARISA Trial, Ranozex therapy significantly reduces <span class="highlight">NTG consumption</span> per week.</li>
		<li>According to ROLE Trial, Ranozex ensures long-term safety in high-risk <span class="highlight">CHD patients</span>.</li>
	  </ul>

	  
	</div>
  </body>
</html>
